Advaxis Announces Appointment of New Member to Its Board of Directors
July 16 2013 - 7:30AM
Business Wire
Advaxis, Inc., (OTCQB: ADXS and ADXSD), a leader in developing
the next generation of immunotherapies for cancer and infectious
diseases, announced the appointment of David Sidransky, MD to its
Board of Directors.
Dr. Sidransky is a renowned oncologist and research scientist
named and profiled by TIME magazine in 2001 as one of the top
physicians and scientists in America, recognized for his work with
early detection of cancer. Since 1994, Dr. Sidransky has been the
Director of the Head and Neck Cancer Research Division and
Professor of Oncology, Otolaryngology, Genetics, and Pathology at
Johns Hopkins University School of Medicine.
He has served as Chairman of the Board of Directors of Champions
Oncology since October 2007 and was, until the merger with Eli
Lilly, a director and Vice-Chairman of ImClone Systems, Inc. He is
the Chairman of Tamir Biotechnology and serves on the Board of
Directors of Rosetta Genomics, Immune Pharmaceuticals, and
Celsus. He is serving and has served on scientific advisory
boards of MedImmune, Roche, Amgen, and Veridex, LLC (a Johnson
& Johnson diagnostic company), among others. Dr. Sidransky
served as Director (2005-2008) of the American Association for
Cancer Research (AACR).
“David’s extensive experience with both the science and business
of oncology makes him an ideal addition to the Board of Directors
of Advaxis,” commented Thomas A. Moore, Chairman and Chief
Executive Officer of Advaxis. “His guidance and high standards will
be invaluable in the advancement of Advaxis’ novel technology to
registrational trials and beyond.”
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing the
next generation of immunotherapies for cancer and infectious
diseases. Advaxis immunotherapies are based on a novel platform
technology using live, attenuated bacteria that are bio-engineered
to secrete an antigen/adjuvant fusion protein(s) that is designed
to redirect the powerful immune response all human beings have to
the bacterium to the cancer itself.
ADXS-HPV is currently being evaluated in four clinical trials
for human papillomavirus (HPV)-associated cancers:
recurrent/refractory cervical cancer (India), locally advanced
cervical cancer (GOG/NCI U.S. study, Clinical Trials.gov Identifier
NCT01266460), head & neck cancer (CRUK study, Clinical
Trials.gov Identifier NCT01598792), and anal cancer (BrUOG study,
Clinical Trials.gov Identifier NCT01671488). Advaxis has over 15
distinct immunotherapies in various stages of development,
developed directly by Advaxis and through strategic collaborations
with recognized centers of excellence such as: the National Cancer
Institute, Cancer Research – UK, the Wistar Institute, the
University of Pennsylvania, the University of British Columbia, the
Karolinska Institutet, and others. For more information please
visit: advaxis.com | Facebook | twitter
| LinkedIn
Forward-Looking Statements
This news release contains forward-looking
statements, including, but not limited to: statements
that David Sidransky’s guidance and high standards will be
invaluable in the advancement of Advaxis’ novel technology to
registrational trials and beyond. These forward-looking
statements are subject to a number of risks, including the risk
factors set forth from time to time in Advaxis' SEC filings,
including but not limited to its report on Form 10-K for the fiscal
year ended October 31, 2012, which is available at
http://www.sec.gov. Advaxis undertakes no obligation to
publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events, except as required by law. You are
cautioned not to place undue reliance on any forward-looking
statements.
Participation by Dr. Sidransky does not constitute or imply
endorsement by the Johns Hopkins University or the Johns Hopkins
Hospital and Health System.
Advaxis, Inc.Diana Moore, 609-452-9814Director, Investor
Relations & Business Developmentdmoore@advaxis.com
Advaxis (QX) (USOTC:ADXSD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Advaxis (QX) (USOTC:ADXSD)
Historical Stock Chart
From Jul 2023 to Jul 2024